Compare Stocks → War Over Taiwan? Protect Your Wealth NOW (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARANASDAQ:DVAXNASDAQ:EPZMOTCMKTS:VEGPFNASDAQ:VERU Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.72+3.3%$0.83$0.50▼$4.67$39.53M0.7636,170 shs41,749 shsDVAXDynavax Technologies$11.20+0.3%$12.25$10.06▼$15.15$1.47B1.262.01 million shs279,506 shsEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsVEGPFVectura Group$1.77$1.77$1.64▼$2.74$1.07B0.372,185 shsN/AVERUVeru$1.24+2.5%$0.82$0.36▼$1.92$181.51M-0.212.34 million shs266,537 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics+4.23%+1.45%-4.14%+21.42%-82.50%DVAXDynavax Technologies-2.19%-1.50%-9.70%-16.14%+5.88%EPZMEpizyme0.00%0.00%0.00%0.00%0.00%VEGPFVectura Group0.00%0.00%0.00%0.00%0.00%VERUVeru-8.33%-14.79%+98.39%+181.33%-5.47%War Over Taiwan? Protect Your Wealth NOW (Ad)With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.Access my report now >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.6939 of 5 stars3.41.00.04.21.21.71.3DVAXDynavax Technologies4.3098 of 5 stars3.41.00.04.72.12.51.9EPZMEpizymeN/AN/AN/AN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/AN/AN/AN/AVERUVeru1.3264 of 5 stars3.41.00.00.02.91.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.751,248.55% UpsideDVAXDynavax Technologies2.75Moderate Buy$25.00123.21% UpsideEPZMEpizymeN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AVERUVeru2.75Moderate Buy$3.33168.82% UpsideCurrent Analyst RatingsLatest EPZM, CARA, VERU, VEGPF, and DVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024VERUVeruOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.004/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/28/2024VERUVeruRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.002/23/2024DVAXDynavax TechnologiesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/8/2024VERUVeruHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.002/1/2024DVAXDynavax TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$20.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M1.88N/AN/A$1.05 per share0.69DVAXDynavax Technologies$232.28M6.31N/AN/A$4.81 per share2.33EPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72VEGPFVectura Group$244.76M4.37$0.28 per share6.33$1.16 per share1.53VERUVeru$16.30M11.14N/AN/A$0.22 per share5.64Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)DVAXDynavax Technologies-$6.39M-$0.06N/A26.05N/A-2.75%-1.08%-0.66%5/8/2024 (Confirmed)EPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AVEGPFVectura Group$157.16M$0.266.8117.70N/AN/AN/AN/AN/AVERUVeru-$93.15M-$0.75N/AN/AN/A-405.04%-257.92%-107.27%5/9/2024 (Estimated)Latest EPZM, CARA, VERU, VEGPF, and DVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/ADVAXDynavax Technologies-$0.04N/A+$0.04N/AN/AN/A 4/1/2024Q1 2024VERUVeruN/A-$0.09-$0.09-$0.10N/A$2.14 million3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/AEPZMEpizymeN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43DVAXDynavax Technologies0.4113.8112.96EPZMEpizymeN/A5.355.19VEGPFVectura GroupN/AN/AN/AVERUVeruN/A3.212.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%DVAXDynavax Technologies96.96%EPZMEpizyme76.45%VEGPFVectura GroupN/AVERUVeru47.16%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%DVAXDynavax Technologies2.98%EPZMEpizyme23.40%VEGPFVectura GroupN/AVERUVeru14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.67 million52.37 millionOptionableDVAXDynavax Technologies408130.86 million126.96 millionOptionableEPZMEpizyme250168.33 million128.97 millionOptionableVEGPFVectura Group502604.26 millionN/ANot OptionableVERUVeru189146.38 million125.60 millionOptionableEPZM, CARA, VERU, VEGPF, and DVAX HeadlinesSourceHeadlineVeru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11globenewswire.com - April 25 at 8:30 AMNetflix To Stop Sharing Subscriber Data; Stock Dipsmarkets.businessinsider.com - April 19 at 6:13 PMWhat Makes Veru (VERU) a New Buy Stockzacks.com - April 17 at 1:01 PMVeru (NASDAQ:VERU) Given "Outperform" Rating at Oppenheimeramericanbankingnews.com - April 16 at 3:26 AMVeru (NASDAQ:VERU) Earns "Outperform" Rating from Oppenheimermarketbeat.com - April 15 at 8:29 AMREVEALED: Transport Malta officials at centre of maritime fines corruption racketmaltatoday.com.mt - April 2 at 12:43 AMVeru Announces Date of 2024 Annual Meeting of Shareholdersfinance.yahoo.com - April 1 at 7:43 PMFlag carrier Air Malta ceases operations today, its 50th birthdaymaltatoday.com.mt - March 31 at 6:39 PMVeru Incmorningstar.com - March 29 at 9:35 PMUpdated | Mosta trees vandalised: ERA, police investigatingmaltatoday.com.mt - March 29 at 8:54 AMRaymond James Begins Coverage on Veru (NASDAQ:VERU)marketbeat.com - March 28 at 8:28 AMR&B Realty’s Gateway at Wynwood hit with foreclosure lawsuittherealdeal.com - March 22 at 6:18 PMVeru Reschedules Annual Meeting of Shareholdersglobenewswire.com - March 22 at 4:05 PMWynwood offices targeted in $102M foreclosurebizjournals.com - March 21 at 6:43 PMNaksha Saran plays a bike taxi driver in her next filmmsn.com - March 19 at 4:27 AMPrecise and efficient cutting (sawing) of lightweight core materialsjeccomposites.com - March 18 at 1:24 PMVERU Mar 2024 0.500 putca.finance.yahoo.com - March 16 at 1:30 PMVeru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Lossglobenewswire.com - March 12 at 8:00 AMVERU Mar 2024 1.500 putfinance.yahoo.com - March 11 at 11:33 PMBrussels is mixed bag of emotions on possible Joseph Muscat returnmaltatoday.com.mt - March 11 at 1:32 PMVERU Jan 2025 17.000 callfinance.yahoo.com - March 9 at 6:52 PMVERU Mar 2024 0.500 callfinance.yahoo.com - March 9 at 1:52 PMVERU Mar 2024 3.000 putfinance.yahoo.com - March 9 at 1:52 PMVERU Mar 2024 2.500 putfinance.yahoo.com - March 1 at 11:31 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Dynavax TechnologiesNASDAQ:DVAXDynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.EpizymeNASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Vectura GroupOTCMKTS:VEGPFVectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.VeruNASDAQ:VERUVeru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.